

In Vitro Diagnostic Reagent

Clinical Evaluation Report

Product Name: Rapid SARS-CoV-2 Antigen Test Card

Manufacturer: Xiamen Boson Biotech Co., Ltd.

Clinical Trial Institution: Chongqing Public Health Medical Center

Principal Investigator: Jing Wang

Clinical Statistics Institution: Chongqing Public Health Medical Center

Person Responsible for Clinical Statistics: Kun Yang

Clinical Statistics Institution: Xiamen Boson Biotech Co., Ltd.

Person Responsible for Clinical Statistics: Kesai Liu

Applicant Institution: Xiamen Boson Biotech Co., Ltd.

Address: 90-94 Tianfeng Road, Jimei North Industrial Park,
Xiamen, Fujian, 361021, P.R.China.

Contact: Zhijuan Jia

Report Date: August 25, 2020

Table of Contents

ABSTRACT	I
MAJOR INVESTIGATORS	II
1 OVERVIEW	1
1.1 INTRODUCTION	1
1.1.1 <i>Background for Clinical Trial</i>	1
1.1.2 <i>Product Testing Principle and Methods</i>	1
1.1.3 <i>Intended Use</i>	1
1.2 PURPOSE.....	2
1.3 CLINICAL TRIAL MANAGEMENT	2
1.4 EXPERIMENT DESIGN	2
1.4.1 <i>Description of Overall Experiment Design and Plan</i>	2
1.4.2 <i>Sample Selection and Exclusion Criteria</i>	3
1.4.3 <i>Testing Reagent</i>	4
1.4.4 <i>Quality Control Methods</i>	4
1.4.5 <i>Statistical Analysis Methods</i>	4
1.5 CLINICAL TRIAL RESULTS AND ANALYSIS	5
1.5.1 <i>Sample distribution statistics</i>	5
1.5.2 <i>Statistical analysis of datas</i>	5
2 APPENDIX	6
2.1 RESUME OF PRINCIPAL INVESTIGATORS	6
2.2 CASE REPORT FORMS	7

Abstract

Entrusted by Xiamen Boson Biotech Co., Ltd. ("Boson"), Chongqing Public Health Medical Center carried out the clinical trials of the Rapid SARS-CoV-2 Antigen Test Card ("Evaluated Reagent") manufactured by Boson.

The clinical diagnosis ability and the in-use safety and effectiveness of the Rapid SARS-CoV-2 Antigen Test Card manufactured by Xiamen Boson Biotech Co., Ltd. were evaluated based on comparison with RT-PCR method.

The clinical trials were carried out in strict accordance with the experiment plan. A total of 236 cases were used, including 32 confirmed cases and 204 excluded cases. The test results are summarized below:

Evaluated Reagent Results	RT-PCR Results		Total
	Positive (+)	Negative (-)	
Positive (+)	30	4	34
Negative (-)	2	200	202
Total	32	204	236

Sensitivity = $30/32 \times 100\% = 93.75\%$ (95% CI: 85.36% - 99.99%)

Specificity = $200/204 \times 100\% = 98.04\%$ (95% CI: 96.14% - 99.94%)

Accuracy = $230/236 \times 100\% = 97.46\%$ (95% CI: 95.45% - 99.47%)

Major Investigators

Clinical Trial Investigators	Responsibility	Location
Jing Wang	Principal investigator, statistical analysis	Chongqing Public Health Medical Center
Chengjun Xue	lab quality control, sample management	Chongqing Public Health Medical Center
Kun Yang	Statistical analysis, lab quality control	Chongqing Public Health Medical Center
Jin Shen	Sample management, clinical data organization	Chongqing Public Health Medical Center
Chengli Wei	Test operation, clinical data organization	Chongqing Public Health Medical Center
Duanduan Chen	Test operation, reagent manager	Chongqing Public Health Medical Center

1 Overview

1.1 Introduction

1.1.1 Background for Clinical Trial

COVID-19 is caused by infection with SARS-CoV-2 (novel coronavirus) with major clinical symptoms of fever, cough, and muscle fatigue. The incubation period is 1 to 14 days, mostly 3 to 7 days. A small number of patients can also exhibit nasal congestion, tears, sore throat, myalgia, diarrhea, and other symptoms. Critically ill patients often develop dyspnea and/or hypoxemia one week after disease onset, with severe cases rapidly progressing into acute respiratory distress syndrome, septic shock, metabolic acidosis, coagulation disorder, and multiple organ failure. SARS-CoV-2 is an RNA virus belonging to the β -CoV lineage. It has a viral envelope, is round or oval in shape with approximately 60-140 nm in diameter, and is usually polymorphic.

1.1.2 Product Testing Principle and Methods

1. Testing Principle

Rapid SARS-CoV-2 Antigen Test Card is an immunochromatographic lateral flow device that employs the principle of double antibody sandwich method. Colloidal gold conjugated anti-SARS-CoV-2 antibodies are dry-immobilized on the test device. When the specimen is added, it migrates by capillary diffusion through the strip to re-hydrate the gold conjugate complexes. If present at or above the limit of detection, SARS-CoV-2 viral antigens will react with the gold conjugate complexes to form particles, which will continue to migrate along the strip until the Test Zone (T) where they are captured by the immobilized anti-SARS-CoV-2 antibodies to form a visible red line. If there are no SARS-CoV-2 viral antigens in the specimen, no red line will appear in the Test Zone (T). The gold conjugate complexes will continue to migrate alone until being captured by immobilized antibody in the Control Zone (C) to form a red line, which indicates the validity of the test.

2. Methods

Read the instructions for use carefully before testing. Bring the kit components to room temperature and carry out the test under room temperature.

Refer to the instructions for use for testing procedures.

1.1.3 Intended Use

Rapid SARS-CoV-2 Antigen Test Card is an immunochromatography based one step in vitro test. It is designed for the rapid qualitative determination of SARS-CoV-2 virus antigen in nasopharyngeal swabs from individuals suspected of COVID-19 by their healthcare

provider within the first seven days of symptom onset. Rapid SARS-CoV-2 Antigen Test Card can not be used as the basis to diagnose or exclude SARS-CoV-2 infection.

1.2 Purpose

To evaluate the clinical diagnosis ability and the in-use safety and effectiveness of the Rapid SARS-CoV-2 Antigen Test Card manufactured by Xiamen Boson Biotech Co., Ltd.

1.3 Clinical Trial Management


1. Quality control of clinical test conditions and personnel: Before the clinical test is carried out, the department undertaking the clinical test shall check and confirm that the test equipment and instruments are running normally, the reagent is within the effective period and the storage conditions meet the requirements of the kit. Test personnel are trained and able to meet test requirements.
2. Quality control during the clinical trial: This clinical trial adopted a blind controlled trial design, and the samples were blinded. Neither the sample tester nor the result observer knew about the blindness of the samples. It can effectively reduce the bias of test results and ensure the quality of clinical trials. The acquisition, preservation and test operation of samples shall be carried out in strict accordance with the program, and clinical supervisors shall be assigned to supervise the implementation of clinical trials.
3. Quality control of clinical trial results: control products are set to ensure the reliable quality of experimental results.
4. The main researcher should appoint experienced personnel in his department to carry out the experiment and judge the results.
5. The operation of clinical trials shall be carried out in strict accordance with standard operating procedures.

1.4 Experiment Design

1.4.1 Description of Overall Experiment Design and Plan

1. Methods

In this clinical trial, blind data analysis was adopted and the Rapid SARS-CoV-2 Antigen Test Card manufactured by Xiamen Boson Biotech Co., Ltd. was used to compare and study the detection results of the samples with the RT-PCR method. The specific test process is as follows:



2. Selection of Clinical Trial Institutions

The clinical trials were conducted in Chongqing Public Health Medical Center. The hospital has the technical personnel and relevant experiences in clinical trial projects to ensure the successful implementation of the clinical trials.

3. Number of samples

Confirmed samples: at least 30 cases.

Excluded samples: at least 50 cases.

4. Sample type

Nasopharyngeal swab samples from the patients.

1.4.2 Sample Selection and Exclusion Criteria

1. Inclusion Criteria:

- a. COVID-19 suspected cases (confirmed cases, excluded cases) were selected.
- b. No limitation on gender and age.
- c. The patient information and clinical test/diagnosis information of the samples can be completely traced.

2. Exclusion Criteria:

- a. Insufficient sample size.
- b. Improper storage of samples.
- c. Others deemed reasonable by the principal investigator.

3. Rejection Criteria:

- a. Incomplete case history or failure to meet the inclusion criteria.
- b. The normal test cannot be completed due to equipment or operation factors (the sample is contaminated during operation and the sample size is insufficient).
- c. Samples deemed inappropriate by the principal investigator.

1.4.3 Testing Reagent

A. Evaluated Reagent

Reagent Name: Rapid SARS-CoV-2 Antigen Test Card

Manufacturer: Xiamen Boson Biotech Co., Ltd.

Packaging: 20 tests/kit

Storage: 4-30°C, sealed and stored in dry conditions

B. Comparator Method: RT-PCR method

Reagent Name: Detection Kit for 2019-nCoV (PCR-Fluorescence)

Manufacturer: Da An Gene Co., Ltd. of Sun Yat-sen University

1.4.4 Quality Control Methods

1. Adopt unified technical methods in the same laboratory. Evaluation should be performed by the same testing personnel in strict accordance with the reagent operation procedures.
2. Indoor quality control should be carried out for each test.

1.4.5 Statistical Analysis Methods

1. The sensitivity, specificity, accuracy and confidence interval were calculated by comparing the detection results of Evaluated Reagent with RT-PCR (see Table 1).

Table 1 Comparison of test results for the Evaluated Reagent and RT-PCR

Evaluated Reagent Results	RT-PCR Results		Total
	Positive (+)	Negative (-)	
Positive (+)	a	b	a+b
Negative (-)	c	d	c+d
Total	a+c	b+d	a+b+c+d

Sensitivity= $a/(a+c) * 100\%$;

Specificity= $d/(b+d) * 100\%$;

Accuracy= $(a+d)/(a+b+c+d) * 100\%$

2. Performance evaluation as in the following table

Table 2 Performance Evaluation as in the Following Table

	n	N	n/N	%	95%CI
Clinical Sensitivity (95% CI), N					
Sensitivity days \leq 7, N					
Sensitivity Ct \leq 33, N					
Sensitivity Ct \leq 25, N					
Clinical Specificity (95%CI), N					
Invalid rate (% , n/N)					
Analytical Sensitivity (pfu/ml)					

1.5 Clinical Trial Results and Analysis

1.5.1 Sample distribution statistics

A total of 236 samples were used for the clinical trials, including 32 confirmed cases, and 204 excluded cases.

Table 3 Sample Distribution

	Number
Confirmed Cases	32
Excluded Cases	204
Total	236

Table 4 Detailed Information of Samples

	n	N	n/N	%
Gender [%F,(n/N)]	117	236	117/236	49.6%
Days <0-3, (n, %)	19	32	19/32	59.4%
Days 4-7, (n, %)	13	32	13/32	40.6%
Positivity [%, (n/N)]	30	32	30/32	93.8%
PCR Ct [median(Q1-Q3); N]	24.7; 32			
Ct>30 (n, %)	3	32	3/32	9.4%
Ct>25 (n, %)	14	32	14/32	43.8%

1.5.2 Statistical analysis of datas

Table 5 Comparison of test results for the Evaluated Reagent and RT-PCR

Evaluated Reagent Results	RT-PCR Results		Total
	Positive (+)	Negative (-)	
Positive (+)	30	4	34
Negative (-)	2	200	202
Total	32	204	236

Sensitivity = $30/32 \times 100\% = 93.75\%$ (95% CI: 85.36% - 99.99%)

Specificity = $200/204 \times 100\% = 98.04\%$ (95% CI: 96.14% - 99.94%)

Accuracy = $230/236 \times 100\% = 97.46\%$ (95% CI: 95.45% - 99.47%)

Table 6 Performance Evaluation as in the Following Table

	n	N	n/N	%	95%CI
Clinical Sensitivity (95% CI), N	30	32	30/32	93.75%	85.36%-99.99%
Sensitivity days≤7, N	30	32	30/32	93.75%	85.36%-99.99%
Sensitivity Ct≤33, N	30	32	30/32	93.75%	85.36%-99.99%
Sensitivity Ct≤25, N	18	18	18/18	100.00%	99.53%-99.99%
Clinical Specificity (95%CI), N	200	204	200/204	98.04%	96.14%-99.94%
Invalid rate (%, n/N)	0	0	0/236	0	/
Analytical Sensitivity (pfu/ml)	1.3×10 ² TCID ₅₀ /mL				

2 Appendix

2.1 Resume of Principal Investigators

Name	Jing Wang	Date of Birth	1975.06
Sex	Female	Major	Clinical Laboratory
Education	Undergraduate	Degree	Master
Workplace	Chongqing Public Health Medical Center	Department	Clinical Laboratory
Position	Department Director	Title	Deputy Senior Technologist
GCP Qualification	Pass	Last Acquisition Date	2019.6.5
Certificate No.	CQGWGCP-2019091		

Education

Start / End Date	School	Major	Degree
1994.9-1999.7	Chongqing Medical University	Clinical Laboratory	Bachelor
2012.3-2016.6	Sichuan University	Biomedical Engineering	Master

Work Experience

Start / End Date	Workplace	Department
1999.7-present	Chongqing Public Health Medical Center	Clinical Laboratory

Training

Start / End Date	Training Agency	Training Name	Training Type
2017.6.24-26	Drug Clinical Research Training Center of the People's Liberation Army	Quality management standards for clinical trials of medical devices	GCP
2018.7.6	Drug Clinical Trial Institution of Chongqing Public Health Medical Center	Training course on medical device GCP and ethics review	GCP
2019.6.1	Drug Clinical Trial Institution of Chongqing Public Health Medical Center	Clinical training on drug and medical devices based on major infectious diseases	GCP

Clinical Trial Experience

Start / End Date	Specialty	Test Name	Role
2017.6-2018.10	Clinical Testing	HIV-1 Nucleic Acid Virus Test Kit (RT-PCR)	Principal Investigator
2018.8-2019.1	Clinical Testing	HIV-1 Nucleic Acid (RNA) Test Kit (PCR)	Principal Investigator
2018.8-2019.1	Clinical Testing	Mycobacterium Tuberculosis Specific Cellular Immune Response Test Kit (ELISA)	Investigator, Quality Control
2019.3-2019.9	Clinical Testing	HIV-1 Nucleic Acid Virus Test Kit (TMA)	Principal Investigator
2018.10-Present	Clinical Testing	Cryptococcus Circulating Antigen Test Kit (Latex Immunochromatography)	Principal Investigator

2.2 Case Report Forms

Case Report Form

No.	Patient Number	Sex	Age	Sample Type	Clinical Diagnosis Background Info	Evaluated Reagent Results	Nucleic Acid Test Results	Nucleic Acid Testing Value	Disease Onset Time	Sample Collection Time	Test Time of Evaluated Reagent	Test Time of RT-PCR
1	00251325	M	32	NP	COVID-19, Fever, Dry cough, Wheezing, Shortness of breath, etc.	+	+	25	5 days	2020/06/17	2020/06/17	2020/06/17
2	00751236	F	68	NP	COVID-19, Low fever, Close contacts of COVID-19	+	+	29	1 day	2020/06/17	2020/06/17	2020/06/17
3	00751269	F	28	NP	COVID-19, Dizzy, Cough, White foam sputum, Chest tightness, Shortness of breath, Chest pain	+	+	21.5	4days	2020/06/19	2020/06/19	2020/06/19
4	00251382	M	31	NP	COVID-19, Dry cough, Close contacts of COVID-19	+	+	21	1 day	2020/06/19	2020/06/19	2020/06/19
5	00251398	F	71	NP	COVID-19, Fever, Chills, Weakness	+	+	22	5 days	2020/06/21	2020/06/21	2020/06/21
6	00125781	F	69	NP	COVID-19, Cough, Fever	+	+	24.3	2 days	2020/06/21	2020/06/21	2020/06/21
7	00125479	F	34	NP	COVID-19, Fever, Close contacts of COVID-19	+	+	23.3	2 days	2020/06/23	2020/06/23	2020/06/23
8	00795413	M	35	NP	COVID-19, Chills, Fever, Radiographs of the basal segment in the lower lobe of the right lung	+	+	27	4 days	2020/06/23	2020/06/23	2020/06/23
9	00784512	F	29	NP	COVID-19, Fever, Diarrhea, Dry cough, Recurrent fever	+	+	22.6	2 days	2020/06/24	2020/06/24	2020/06/24

10	00326598	M	21	NP	COVID-19, Chills, Dry cough, Close contacts of COVID-19	-	+	32	7 days	2020/06/27	2020/06/27	2020/06/27
11	00852149	M	55	NP	COVID-19, Fever, Headache, Weakness	+	+	23	1 day	2020/06/29	2020/06/29	2020/06/29
12	00781254	F	54	NP	COVID-19, Diarrhea, Low fever	+	+	21	3 days	2020/06/30	2020/06/30	2020/06/30
13	00795100	M	54	NP	COVID-19, Dry cough, Wheezing, Shortness of breath	+	+	22	4 days	2020/07/03	2020/07/03	2020/07/03
14	00154795	M	59	NP	COVID-19, Dry cough, With sputum, Cough, Pharyngalgia, Chills, Fever, etc.	+	+	24.2	2 days	2020/07/05	2020/07/05	2020/07/05
15	00854692	M	15	NP	COVID-19, Fever, Cough, Nasal obstruction, Pharyngalgia, CT showed more lung lesions	+	+	23.1	5 days	2020/07/06	2020/07/06	2020/07/06
16	00257413	F	37	NP	COVID-19, Fever, Close contacts of COVID-19	+	+	28	1 day	2020/07/10	2020/07/10	2020/07/10
17	00306054	F	32	NP	COVID-19, Dizziness and nausea, Pharyngalgia, Nasal obstruction, Anorexia, Poor appetite, Weakness	+	+	27.4	2 days	2020/07/10	2020/07/10	2020/07/10
18	00309058	M	46	NP	COVID-19, Fever	+	+	22	2 days	2020/07/15	2020/07/15	2020/07/15
19	00240560	F	62	NP	COVID-19, Fever, Cough, Sputum is difficult	+	+	27	6 days	2020/07/16	2020/07/16	2020/07/16

					to cough up, Close contacts of COVID-19							
20	00025416	M	31	NP	COVID-19, Fever, Close contacts of COVID-19	+	+	25.5	4 days	2020/07/18	2020/07/18	2020/07/18
21	00820156	M	16	NP	COVID-19, Close contacts of COVID-19, Dry cough, etc.	+	+	23.6	1 day	2020/07/20	2020/07/20	2020/07/20
22	00854120	F	48	NP	COVID-19, Throat discomfort	+	+	25.2	2 days	2020/07/23	2020/07/23	2020/07/23
23	00305701	M	24	NP	COVID-19, Fever, Cough, Cough with white phlegm, etc.	+	+	26	2 days	2020/07/23	2020/07/23	2020/07/23
24	00201781	F	42	NP	COVID-19, Fever	+	+	27.1	2 days	2020/07/27	2020/07/27	2020/07/27
25	00985201	F	45	NP	COVID-19, Fever, Anorexia	+	+	31.2	4 days	2020/07/27	2020/07/27	2020/07/27
26	00950213	F	59	NP	COVID-19, Fever	-	+	31	6 days	2020/07/29	2020/07/29	2020/07/29
27	00980215	M	17	NP	COVID-19, Fever	+	+	24	2 days	2020/07/31	2020/07/31	2020/07/31
28	00320150	F	14	NP	COVID-19, Chills, Dry cough, etc.	+	+	25	2 days	2020/08/02	2020/08/02	2020/08/02
29	00905087	M	51	NP	COVID-19, Dry cough, Wheezing, Shortness of breath, etc.	+	+	22.5	2 days	2020/08/06	2020/08/06	2020/08/06
30	00305099	F	52	NP	COVID-19, Fever	+	+	24.4	1 day	2020/08/11	2020/08/11	2020/08/11
31	00906033	M	44	NP	COVID-19, High fever, CT showed hyaline shadow in the dorsal segment of the lower lobe of both lungs, Calcification in right lower lobe of lung	+	+	26.5	6 days	2020/08/18	2020/08/18	2020/08/18

32	00805521	M	76	NP	COVID-19, Fever, Cough, etc.	+	+	26.3	4 days	2020/08/19	2020/08/19	2020/08/19
33	00250132	M	71	NP	AIDS	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
34	00891255	F	32	NP	Tuberculosis	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
35	00895644	F	50	NP	AIDS	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
36	00959699	F	35	NP	Lung Shadow	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
37	QY221133	M	60	NP	Tuberculosis	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
38	00984500	M	40	NP	Tuberculous Meningitis	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
39	00959668	M	24	NP	Cough to be tested	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
40	00784511	F	32	NP	Tuberculosis	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
41	00232544	F	21	NP	Fever to be tested	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
42	00665822	F	22	NP	Tuberculosis re-treatment	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
43	00895655	F	50	NP	Tuberculosis, Culture-positive, Tracheal Tuberculosis	+	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
44	00789865	F	30	NP	Fever to be tested	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
45	00626577	M	14	NP	Tuberculosis re-treatment	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
46	00230859	F	55	NP	Fever to be tested	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
47	00258907	M	7	NP	Fever to be tested, Obsolete Tuberculosis,	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
48	00556987	M	76	NP	Cough to be tested	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
49	00834102	F	34	NP	Fever to be tested: 1) bacterial? 2) viral?, Hypothyroidism	+	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
50	00897744	M	25	NP	Fever to be diagnosed	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
51	00652230	M	64	NP	Pneumonia recovery period	-	-	> 40	/	2020/06/17	2020/06/17	2020/06/17
52	00451288	F	34	NP	Fever to be diagnosed	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
53	00449988	F	25	NP	Fever to be tested: Lung Infection?	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19

54	00367856	M	39	NP	Pneumonia recovery period	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
55	00895841	F	42	NP	Trochanteric fracture of left femur	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
56	00369500	F	41	NP	Trochanteric fracture of left femur	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
57	00022288	F	31	NP	URTI?	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
58	00897488	M	31	NP	Fever to be diagnosed	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
59	00895564	M	85	NP	Trochanteric fracture of left femur	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
60	00848522	F	74	NP	COPD with acute exacerbation	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
61	00784152	M	21	NP	Community Acquired Pneumonia, non-severe	-	-	> 40	/	2020/06/19	2020/06/19	2020/06/19
62	00919298	F	51	NP	Community Acquired Pneumonia	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
63	00353634	M	24	NP	Fell and hurt	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
64	00895264	F	33	NP	Community Acquired Pneumonia, non-severe	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
65	00514278	M	64	NP	COPD with acute exacerbation	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
66	00859500	F	65	NP	Pulmonary Heart Disease	+	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
67	00874592	M	8	NP	AIDS	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
68	00369504	M	31	NP	Early Pregnancy Miscarriage	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
69	00892510	M	47	NP	AIDS	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
70	00854621	F	61	NP	Early Pregnancy Miscarriage	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
71	00522369	M	36	NP	Lung Shadow	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21
72	00355874	F	32	NP	AIDS	-	-	> 40	/	2020/06/21	2020/06/21	2020/06/21

73	00951166	M	82	NP	Tuberculosis	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
74	00855241	F	73	NP	Tuberculosis	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
75	00984517	M	21	NP	Cervical and abdominal lymph node TB	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
76	00958411	F	24	NP	AIDS	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
77	00652955	M	47	NP	Tuberculosis	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
78	00665655	F	80	NP	AIDS	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
79	00454488	M	35	NP	AIDS	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
80	00852159	F	54	NP	Cervical and abdominal lymph node TB	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
81	00233663	F	18	NP	Lung Shadow	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
82	00255874	M	24	NP	Tuberculosis, post-operative multiple-drug resistance	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
83	00599887	M	47	NP	Chronic HBV	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
84	00110022	F	15	NP	Lung Shadow	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
85	00369885	F	54	NP	AIDS, Tuberculosis, Drug-induced liver damage	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
86	00254471	M	47	NP	Upper Gastrointestinal Bleeding	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
87	00995887	M	58	NP	Abdominal distention to be tested	-	-	> 40	/	2020/06/23	2020/06/23	2020/06/23
88	00330022	F	31	NP	Fever to be tested	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
89	00322010	F	10	NP	AIDS, Tuberculosis, Drug-induced liver damage	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
90	00652144	F	45	NP	Fever to be tested	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
91	00998544	M	25	NP	Abdominal distention to be tested	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24

92	00887744	F	42	NP	Liver Cirrhosis	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
93	00995580	M	19	NP	HBV	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
94	00459822	M	21	NP	Upper Gastrointestinal Bleeding	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
95	00356620	F	23	NP	HBV	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
96	00885410	M	23	NP	AIDS, Lung Infection, Headache to be tested	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
97	00225580	F	43	NP	Lung Shadow,	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
98	00285933	F	35	NP	Cough to be tested	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
99	00854112	F	60	NP	Lung Shadow	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
100	00511211	M	26	NP	Tuberculosis	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
101	00854499	M	51	NP	Secondary Tuberculosis (re-treatment, multiple drug resistance) smear- and culture-positive, Bronchial Tuberculosis, Drug-Induced Liver Injury, Vitamin B6 deficiency	-	-	> 40	/	2020/06/24	2020/06/24	2020/06/24
102	00478123	F	65	NP	Fever	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
103	00058741	F	15	NP	AIDS, fever to be tested	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
104	00562394	M	53	NP	Fever	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
105	00251100	M	10	NP	Fever to be tested	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
106	00360001	F	29	NP	Lung Shadow	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
107	00620015	F	30	NP	Fever to be tested	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
108	00259901	F	41	NP	Acute Tonsillitis	-	-	> 40	/	2020/06/29	2020/06/29	2020/06/29
109	00851200	F	74	NP	AIDS, fever to be tested	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
110	00362200	F	49	NP	Fever to be tested?	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
111	00952600	M	20	NP	Fever to be diagnosed	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30

112	00954127	M	46	NP	Acute Tonsillitis	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
113	00145203	F	23	NP	Fever to be diagnosed	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
114	00120522	M	54	NP	Fever to be diagnosed	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
115	00895210	M	11	NP	Acute Tonsillitis	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
116	00951400	F	67	NP	Fever to be diagnosed, Enteritis?	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
117	00259401	F	19	NP	Lung Infection?	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
118	00950608	M	11	NP	Acute Tonsillitis	-	-	> 40	/	2020/06/30	2020/06/30	2020/06/30
119	00060305	M	19	NP	Intrauterine adhesions following miscarriage, HIV	-	-	> 40	/	2020/07/05	2020/07/05	2020/06/30
120	00080541	M	26	NP	URTI?	-	-	> 40	/	2020/07/05	2020/07/05	2020/06/30
121	00950103	M	48	NP	URTI?	-	-	> 40	/	2020/07/05	2020/07/05	2020/06/30
122	00540102	F	51	NP	Lung Infection, Fever	-	-	> 40	/	2020/07/05	2020/07/05	2020/06/30
123	00062051	M	10	NP	Chest tightness to be tested	-	-	> 40	/	2020/07/05	2020/07/05	2020/06/30
124	00902056	F	23	NP	Community Acquired Pneumonia	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
125	00050288	M	27	NP	Chest tightness to be tested	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
126	00014650	M	41	NP	HIV, Liver Space Occupying: Primary Liver Cancer	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
127	00025413	F	44	NP	Lung Infection, Fever	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
128	00259850	F	29	NP	Back pain to be tested	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
129	00365299	M	58	NP	COPD with acute exacerbation	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
130	00369870	M	23	NP	Bronchial Asthma	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
131	00958210	M	44	NP	HIV, Cervical Cancer	-	-	> 40	/	2020/07/05	2020/07/05	2020/07/05
132	00845120	F	12	NP	COPD with acute	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10

					exacerbation							
133	00952122	M	35	NP	Lung Shadow	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
134	00952163	F	13	NP	HIV, Cervical Cancer	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
135	00952361	F	64	NP	Chronic HBV, fever	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
136	00320654	M	21	NP	Cough to be tested	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
137	00265840	F	72	NP	Renal Pelvis Tumor, Acute Gastroenteritis	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
138	00952140	F	32	NP	Ectopic Pregnancy	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
139	00985213	F	63	NP	HIV, Cervical Cancer	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
140	00569245	F	70	NP	Community Acquired Pneumonia	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
141	00251162	M	82	NP	COPD with acute exacerbation	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
142	00258945	F	84	NP	Fever to be tested? Severe Malnutrition	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
143	00974844	M	26	NP	Cough to be tested	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
144	00954874	F	35	NP	Community Acquired Pneumonia, non-severe	-	-	> 40	/	2020/07/10	2020/07/10	2020/07/10
145	00949491	M	54	NP	Diabetes	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
146	00858481	F	32	NP	Fever to be tested? Severe Malnutrition	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
147	00848600	F	50	NP	Community Acquired Pneumonia, non-severe	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
148	00848501	F	85	NP	Lung Infection	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
149	00352011	M	62	NP	COPD	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
150	00205301	F	52	NP	Acute Bronchitis? Community Acquired Pneumonia?	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
151	00501203	M	71	NP	Asthma to be tested	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
152	00602301	F	55	NP	COPD with acute	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16

					exacerbation							
153	00805403	F	90	NP	Skin ulcer of both legs to be tested	+	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
154	00523017	M	90	NP	COPD	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
155	00952013	F	86	NP	COPD with acute exacerbation	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
156	00521462	M	44	NP	Missed Miscarriage?	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
157	00985236	F	92	NP	Fever to be tested, lung infection?	-	-	> 40	/	2020/07/16	2020/07/16	2020/07/16
158	00201145	M	54	NP	Intrauterine Device Incarceration	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
159	00958221	M	22	NP	Missed Miscarriage?	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
160	00457811	F	31	NP	Expected Parturition	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
161	00958213	F	51	NP	HBV (HBsAg, HBeAb, and HBcAb positive), Fever	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
162	00251365	F	61	NP	AIDS	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
163	00895556	M	25	NP	Community Acquired Pneumonia	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
164	00124444	M	34	NP	AIDS	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
165	00158620	M	52	NP	Tuberculosis	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
166	00122056	F	72	NP	AIDS	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
167	00854123	M	31	NP	COPD with acute exacerbation	-	-	> 40	/	2020/07/23	2020/07/23	2020/07/23
168	00122056	M	41	NP	AIDS	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
169	00133330	F	45	NP	Community Acquired Pneumonia	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
170	00144982	M	42	NP	Tuberculosis	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
171	00125920	F	34	NP	Tuberculosis, HBV Carrier	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31

172	00111523	F	45	NP	AIDS	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
173	00133365	M	22	NP	Tuberculosis	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
174	00155558	M	41	NP	AIDS	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
175	00321523	M	25	NP	Tuberculosis	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
176	00689500	M	22	NP	AIDS	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
177	00114777	F	32	NP	Chest tightness to be tested	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
178	QY006589	F	42	NP	Tuberculosis	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
179	00225557	F	62	NP	AIDS	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
180	00255889	F	64	NP	Tuberculosis, HBV Carrier	-	-	> 40	/	2020/07/31	2020/07/31	2020/07/31
181	00562333	M	32	NP	Chest tightness to be tested	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
182	00895541	M	45	NP	AIDS,	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
183	00999958	M	71	NP	Tuberculous Pleurisy	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
184	00254441	F	33	NP	Tuberculosis, Leukopenia, HBV	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
185	00263366	M	31	NP	Secondary Tuberculosis	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
186	00025413	M	55	NP	HIV,	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
187	00250300	F	21	NP	Tuberculosis, Leukopenia, HBV	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
188	00005523	F	61	NP	Tuberculosis recovered, off drugs and re-checked	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
189	00805410	F	31	NP	NTM	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
190	00874516	F	52	NP	Tuberculous Meningitis	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
191	00850012	M	65	NP	Tuberculosis	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
192	00950014	M	64	NP	Tuberculosis (drug resistance)	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
193	00006230	F	42	NP	AIDS	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
194	00260120	M	46	NP	Tuberculous Meningitis	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06

195	00895201	M	62	NP	Fever to be tested	-	-	> 40	/	2020/08/06	2020/08/06	2020/08/06
196	00254610	M	41	NP	Tuberculosis	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
197	00851245	M	21	NP	Cervical Lymph Node Tuberculosis	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
198	00952277	F	21	NP	Tuberculosis	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
199	00256662	M	56	NP	NTM	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
200	00654821	M	56	NP	AIDS	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
201	00952145	F	40	NP	Fever to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
202	2003230154	M	70	NP	Tuberculosis	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
203	2003504612	F	61	NP	Fever to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
204	2003854921	F	11	NP	Cervical Lymph Node Tuberculosis	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
205	2003555692	M	41	NP	AIDS	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
206	2003987502	M	66	NP	Tuberculosis, Bronchial Tuberculosis	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
207	2003541235	F	61	NP	Chest Pain	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
208	2003805462	M	49	NP	AIDS	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
209	2003225410	M	14	NP	Bronchial Tuberculosis, Leukopenia	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
210	2003950025	F	28	NP	Chronic HBV	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
211	2003980566	M	41	NP	Secondary Tuberculosis (re-treatment, multiple drug resistance) smear-negative and culture-positive, Malnutrition, Type II Diabetes	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
212	2003006541	M	18	NP	Fever to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
213	2003044511	F	23	NP	Sore throat to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
214	2003336600	M	71	NP	Chronic HBV	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
215	2003562210	F	25	NP	Chest tightness to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11

216	2003854120	M	32	NP	Fever, diarrhea, abdominal distention to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
217	2003501120	M	52	NP	Fever to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
218	2003995470	M	12	NP	Sore throat to be tested	-	-	> 40	/	2020/08/11	2020/08/11	2020/08/11
219	2003112050	F	53	NP	Chest pain to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
220	2003952241	F	17	NP	Fever to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
221	2003992561	M	53	NP	Chest pain to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
222	2003553260	M	58	NP	Thoracic Abscess	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
223	2003298504	M	49	NP	Pharyngeal Bronchitis	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
224	2003204580	M	18	NP	Fever to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
225	2003220561	F	52	NP	Fever and emesia to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
226	2003223607	F	14	NP	Fever to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
227	2003220874	F	18	NP	Chest tightness to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
228	2003659820	M	28	NP	Cough to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
229	2003260145	F	68	NP	Fever: Pharynx Tonsillitis	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
230	2003952600	M	15	NP	AIDS	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
231	202841203	M	28	NP	Chronic HBV	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
232	202562014	M	36	NP	Pyogenic Tonsillitis	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
233	202801520	F	23	NP	Fever, Sore Throat	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
234	202569230	F	50	NP	Fever to be tested	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
235	202821543	M	47	NP	Chronic HBV with δ factor	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19
236	202892561	F	06	NP	Pharyngeal Bronchitis	-	-	> 40	/	2020/08/19	2020/08/19	2020/08/19